# Vitamin D Deficiency Health Outcomes and Supplementation

## Introduction to the Vitamin D Paradigm

The physiological understanding of vitamin D has evolved substantially over the past century. Initially isolated as the active agent in cod liver oil responsible for curing rickets, vitamin D was long categorized strictly as an essential nutrient for calcium homeostasis and skeletal integrity. However, the identification of the vitamin D receptor (VDR) and the 1-alpha-hydroxylase enzyme in tissues throughout the human body—including the brain, prostate, breast, colon, and immune cells—shifted the scientific consensus [cite: 1, 2, 3]. By the early 2000s, observational epidemiology consistently correlated low serum 25-hydroxyvitamin D [25(OH)D] concentrations with increased risks of cardiovascular disease, autoimmune disorders, psychiatric illnesses, and various malignancies [cite: 4, 5, 6, 7].

This robust epidemiological correlation catalyzed a global public health phenomenon. Routine serum 25(OH)D testing became one of the most frequently ordered laboratory assays, costing healthcare systems hundreds of millions of dollars annually [cite: 8]. Concurrently, high-dose vitamin D supplementation became ubiquitous. Yet, the assumption that correcting a low 25(OH)D level would reliably prevent these chronic diseases was predicated largely on observational data, which is inherently vulnerable to reverse causation and confounding variables. Specifically, chronic illness often limits outdoor activity and degrades dietary intake, meaning low vitamin D may serve as a biomarker of poor health rather than its primary cause [cite: 1, 9].

Over the past decade, the results of massive, placebo-controlled randomized clinical trials (RCTs) have fundamentally challenged the pleiotropic "vitamin D hypothesis" in the general healthy population [cite: 8, 10, 11]. In August 2024, the Endocrine Society published a landmark Clinical Practice Guideline that dramatically restructured preventive endocrinology [cite: 6, 10, 12, 13]. The updated consensus advocates against routine 25(OH)D screening for the general public and recommends targeted, empiric supplementation exclusively for specific clinical populations [cite: 8, 10, 13, 14]. This report synthesizes current research on vitamin D synthesis, diagnostic thresholds, testing artifacts, clinical health outcomes, and optimal dosing strategies.

## Synthesis, Metabolism, and Bioavailability

Vitamin D is a pre-hormone that must undergo a sequence of metabolic conversions to achieve biological activity. The cutaneous synthesis of cholecalciferol (vitamin D3) is initiated when solar ultraviolet B (UVB) radiation penetrates the epidermis, converting 7-dehydrocholesterol into previtamin D3, which rapidly isomerizes into cholecalciferol [cite: 15, 16, 17]. 

### Factors Influencing Cutaneous Synthesis

Cutaneous synthesis is heavily modulated by environmental and physiological variables. The zenith angle of the sun, determined by geographical latitude and season, dictates UVB penetration. At latitudes above 50°N (e.g., Berlin, London), UVB wavelengths between 295 nm and 300 nm are insufficient to induce synthesis between October and April, a period termed the "vitamin D winter" [cite: 15, 18]. Furthermore, local environmental factors, including ozone concentrations, cloud cover, and atmospheric pollutants, scatter or absorb UVB radiation, further limiting synthesis [cite: 15].

Physiological factors also govern production. Melanin acts as a natural sunscreen; individuals with darker skin pigmentation require greater UVB exposure to synthesize equivalent amounts of cholecalciferol [cite: 19, 20, 21]. Additionally, advancing age and increased body mass index (BMI) negatively impact vitamin D bioavailability. Aging reduces the epidermal concentration of 7-dehydrocholesterol, while the lipophilic nature of vitamin D causes it to sequester in expanded adipose tissue compartments in individuals with obesity, reducing its circulation in the serum [cite: 16, 19]. 

Despite these physiological constraints, recent European multi-center studies utilizing harmonized immunoassay data from over 80,000 participants paradoxically observed higher 25(OH)D concentrations among populations in higher northern latitudes compared to southern Europe [cite: 18]. This inversion of expected epidemiological patterns is attributed to the widespread use of vitamin D supplements and aggressive food fortification policies in northern European nations, highlighting the increasing reliance on exogenous vitamin D sources [cite: 18].

### The Hydroxylation Pathway

Whether synthesized in the skin or absorbed from the diet, vitamin D enters the circulation bound to the vitamin D binding protein (VDBP) and travels to the liver [cite: 22, 23]. Hepatic 25-hydroxylase enzymes (such as CYP2R1 and CYP27A1) convert it into 25-hydroxyvitamin D [25(OH)D], the primary circulating metabolite [cite: 17]. With a half-life of 15 to 21 days, 25(OH)D is the universally accepted biomarker for assessing overall vitamin D status [cite: 17, 24].

To achieve endocrine functionality, 25(OH)D is transported to the kidneys, where the 1-alpha-hydroxylase enzyme (CYP27B1) converts it into 1,25-dihydroxyvitamin D [1,25(OH)2D], the active steroid hormone [cite: 25]. This active form tightly regulates calcium and phosphorus absorption in the gut. When calcium levels drop, the parathyroid glands secrete parathyroid hormone (PTH), which upregulates renal 1-alpha-hydroxylase to increase 1,25(OH)2D production [cite: 26, 27]. To prevent toxicity, excess 1,25(OH)2D induces the enzyme 24-hydroxylase (CYP24A1), which degrades the active hormone into the inactive metabolite 24,25(OH)2D [cite: 17, 22].

## Optimal Blood Levels and Diagnostic Thresholds

The precise serum 25(OH)D concentration that defines "deficiency," "insufficiency," and "adequacy" has been subject to intense clinical debate. Historically, thresholds were calibrated to the point at which PTH was maximally suppressed, ensuring optimal intestinal calcium absorption.

### The 2011 Consensus Divergence

In 2011, two major scientific bodies issued conflicting guidelines. The Institute of Medicine (IOM)—now the National Academy of Medicine (NAM)—concluded that a 25(OH)D level of 20 ng/mL (50 nmol/L) was sufficient to meet the skeletal health needs of 97.5% of the general population [cite: 12, 24]. The NAM asserted that evidence did not support higher targets for the prevention of non-skeletal diseases [cite: 12].

Conversely, the 2011 Endocrine Society Clinical Practice Guideline defined deficiency as levels below 20 ng/mL, insufficiency as 20 to 29 ng/mL, and sufficiency as 30 to 100 ng/mL (75 to 250 nmol/L) [cite: 12, 15, 28]. This higher 30 ng/mL threshold was heavily supported by the International Osteoporosis Foundation (IOF) for older adults, arguing it maximized fracture prevention and muscle strength [cite: 26, 29, 30]. The 10 ng/mL discrepancy between the NAM and the Endocrine Society resulted in profound variations in clinical practice, classifying millions of healthy individuals as "insufficient" and driving widespread testing [cite: 11].

### The 2024 Endocrine Society Paradigm Shift

In August 2024, the Endocrine Society published a comprehensive update to its guidelines, signaling a retreat from universal diagnostic targets. Following an exhaustive review of recent RCT data, the guideline development panel determined that available evidence does not permit the establishment of 25(OH)D thresholds that specifically predict meaningful clinical benefits in the general population [cite: 4, 5, 12, 13]. 

Consequently, the Endocrine Society officially retracted its endorsement of the 30 ng/mL (75 nmol/L) sufficiency target [cite: 5, 6, 12]. Because large-scale clinical trials failed to demonstrate that tailoring doses based on blood tests improves actual health outcomes, the society now advises against routine 25(OH)D screening for the general public, including healthy pregnant individuals, adults with obesity, and populations with dark skin complexions [cite: 6, 10, 13, 19]. The updated clinical framework emphasizes empiric supplementation—prescribing standard doses without prior testing—for specific high-risk groups rather than pursuing a universal serological target [cite: 6, 14].

### International Public Health Frameworks

In Europe, the European Food Safety Authority (EFSA) sets distinct public health parameters. The EFSA generally utilizes a target of 50 nmol/L for adequacy but focuses heavily on setting safe Tolerable Upper Intake Levels (ULs) [cite: 31, 32]. Recent 2024 updates from EFSA maintain the UL for adults, including pregnant and lactating women, at 100 micrograms per day (4,000 IU), while setting lower limits for children (e.g., 50 micrograms or 2,000 IU for ages 1-10) [cite: 33, 34, 35]. 

On a broader public health scale, the World Health Organization (WHO) released guidelines in late 2025 addressing widespread micronutrient deficiencies. Moving entirely away from individual clinical screening, the WHO focuses on the mandatory or voluntary fortification of edible oils and fats with vitamins A and D [cite: 36, 37]. This population-level strategy is intended to seamlessly integrate with global policies targeting noncommunicable diseases, acknowledging that systemic dietary fortification is more practical for eradicating severe clinical deficiency (rickets and osteomalacia) than individualized medical testing [cite: 36].

### Table 1: Comparison of Institutional Vitamin D Guidelines

| Organization | Sufficiency Threshold | Deficiency Threshold | Routine Screening Endorsed? | Maximum Tolerable Upper Intake (Adults) |
| :--- | :--- | :--- | :--- | :--- |
| **Endocrine Society (2024)** | Retracted (previously 30 ng/mL) | Relies on clinical indications | No | 4,000 IU/day |
| **National Academy of Medicine (NAM)** | $\ge$ 20 ng/mL (50 nmol/L) | $<$ 12 ng/mL (30 nmol/L) | No | 4,000 IU/day |
| **European Food Safety Authority (EFSA)** | $\sim$ 50 nmol/L (12.5 ng/mL) | $<$ 30 nmol/L | No | 4,000 IU/day (100 $\mu$g) |
| **Int. Osteoporosis Foundation (IOF)** | $\ge$ 30 ng/mL (75 nmol/L) | $<$ 20 ng/mL (50 nmol/L) | Yes (for high-risk clinical populations) | 4,000 IU/day |

## The Complexities of Testing and the Bioavailability Controversy

The shift away from routine screening is driven not only by the lack of target thresholds but also by the intrinsic flaws of modern 25(OH)D biochemical assays. Standard commercial immunoassays frequently suffer from cross-reactivity, particularly with C3-epimers. Up to 50% of the 25(OH)D measured in adults may consist of the C3-epimer form, which has substantially lower biological activity [cite: 17, 22]. Standard liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies can fail to adequately separate this epimer from the active metabolite, yielding falsely elevated measurements of vitamin D adequacy [cite: 17, 22].

### The "Racial Paradox" of Vitamin D

The diagnostic limitations of 25(OH)D testing are most pronounced when evaluating individuals with dark skin complexions. High concentrations of epidermal melanin effectively scatter UVB radiation, significantly inhibiting cutaneous vitamin D synthesis [cite: 19, 20, 21]. Consequently, Black populations demonstrate a 15- to 20-fold higher prevalence of severe vitamin D deficiency (total 25(OH)D $<$ 20 ng/mL) compared to White populations [cite: 38]. 

Despite these stark laboratory deficiencies, Black individuals generally present with higher bone mineral density (BMD), fewer osteoporotic fractures, and a lower incidence of falls than their White counterparts—a phenomenon formally termed the "vitamin D racial paradox" [cite: 20, 23, 39]. This contradiction has forced researchers to question whether total 25(OH)D is an accurate biomarker for physiological vitamin D status across different ethnic groups.

### The Vitamin D Binding Protein Artifact

In 2013, a highly publicized study by Powe et al. in the *New England Journal of Medicine* proposed a resolution to the racial paradox [cite: 23]. Because roughly 85% to 90% of circulating 25(OH)D is tightly bound to VDBP, and 10% to 15% is loosely bound to albumin, less than 0.1% circulates entirely "free." The free hormone hypothesis posits that only the unbound and bioavailable fractions exert cellular effects [cite: 22, 40]. Powe et al. reported that Black participants possessed significantly lower circulating levels of VDBP due to a genetic polymorphism (the GC-1F variant) [cite: 23, 41]. The authors calculated that the lower VDBP concentration in Black populations mathematically equalized the level of *bioavailable* 25(OH)D between Black and White populations, seemingly explaining the paradox [cite: 23, 41, 42]. 

However, this foundational claim was swiftly dismantled by subsequent methodological investigations [cite: 43, 44]. Endocrinologists demonstrated that the VDBP assay utilized by Powe et al. was a monoclonal antibody assay that was highly specific to a single peptide fragment [cite: 43, 44]. Crucially, this specific monoclonal antibody failed to properly bind to the GC-1F variant of the VDBP protein—the exact variant predominant in populations of African descent [cite: 40, 43, 44, 45]. 

When researchers subsequently analyzed the exact same cohorts using polyclonal antibody assays and proteomic mass spectrometry—methods unaffected by the GC-1F polymorphism—they proved that VDBP concentrations are actually identical between Black and White individuals [cite: 38, 40, 45].

[image delta #1, 0 bytes]

 Because total VDBP levels are equivalent, the accurately measured free and bioavailable 25(OH)D levels in Black populations are proportionately lower, mirroring their total 25(OH)D levels [cite: 40, 45]. The racial paradox remains biologically unexplained by VDBP artifacts, underscoring the Endocrine Society's decision to advise against routine testing in dark-complexioned populations due to the absence of clear, outcome-linked thresholds [cite: 6, 10, 11, 13, 19].



## Clinical Health Outcomes: The Evidence from Mega-Trials

To transcend the limitations of observational epidemiology, researchers launched numerous placebo-controlled mega-trials designed to definitively assess the prophylactic capabilities of vitamin D. The results have been highly nuanced, frequently contradicting earlier observational optimism.

### Skeletal Health, Falls, and Fractures

In severe deficiency states, inadequate intestinal calcium absorption triggers compensatory mechanisms that demineralize the skeleton, leading to rickets in children and osteomalacia in adults [cite: 29, 46]. Yet, in community-dwelling adults, the fracture-prevention benefits of supplementation are less robust. The US Preventive Services Task Force (USPSTF) review concluded that vitamin D supplementation does not significantly reduce the risk of fractures or falls in generally healthy, postmenopausal women and older men [cite: 11]. 

The VITAL (VITamin D and OmegA-3 TriaL) study, an immense 2x2 factorial trial randomizing 25,871 adults to 2,000 IU of vitamin D3 and/or 1 gram of marine omega-3 fatty acids daily for a median of 5.3 years, reported no significant reduction in incident fractures among the overall cohort [cite: 11, 47, 48]. Benefits for bone health appear heavily sequestered within populations that are institutionalized or suffering from severe baseline deficiency, where 800 to 1,000 IU daily is associated with improved muscle strength and reduced fall risk [cite: 29, 30, 49].

### Cancer and Cardiovascular Disease 

The primary mandate of the VITAL study was to evaluate the primary prevention of cancer and cardiovascular disease (CVD). The trial data revealed no significant reduction in the incidence of major adverse cardiovascular events or total invasive cancer incidence (Hazard Ratio [HR] = 0.96; 95% Confidence Interval [CI]: 0.88–1.06) [cite: 2, 50]. 

However, secondary analyses of the VITAL cohort uncovered critical effect modifications. Supplementation was associated with a statistically significant 17% reduction in advanced (metastatic or fatal) cancers (HR = 0.83; 95% CI: 0.69–0.99) [cite: 47]. This benefit became more pronounced when analyses excluded the first two years of follow-up to account for tumor latency [cite: 2]. Most notably, the reduction in advanced cancer was heavily modified by body mass index (BMI). The protective effect was strongest and statistically significant among individuals with a normal BMI ($<$ 25 kg/m$^2$), whereas no benefit was observed in participants with overweight or obesity [cite: 47, 50, 51]. The volumetric dilution of the lipophilic vitamin D molecule within excess adipose tissue likely blunts its physiological efficacy at a standardized dose of 2,000 IU/day.

### Autoimmunity and the Transience of Protection

Mechanistic evidence confirms that the vitamin D receptor (VDR) is densely expressed on immune cells, facilitating localized immunomodulation via 1,25(OH)2D synthesis [cite: 1]. During the active pill-taking phase of the VITAL trial, participants receiving vitamin D exhibited a 22% reduction in the incidence of new-onset autoimmune diseases [cite: 51]. This protective effect appeared to amplify over time, peaking at a 39% risk reduction in the latter years of the intervention [cite: 51, 52]. 

However, subsequent long-term observational follow-up of the VITAL cohort revealed a critical limitation to this mechanism. Two years after the cessation of the trial's intervention phase, the protective effect of vitamin D against autoimmune disease entirely dissipated [cite: 51]. This indicates that vitamin D does not confer permanent epigenetic or immunological reprogramming; its immunomodulatory benefits require continuous, sustained administration.

### Table 2: Primary and Secondary Outcomes of the VITAL Trial

| Health Outcome Evaluated | Primary Result (Hazard Ratio) | Secondary / Subgroup Findings |
| :--- | :--- | :--- |
| **Total Cancer Incidence** | Null (HR 0.96, CI: 0.88-1.06) | Significant reduction observed exclusively in normal BMI ($<$25) individuals. |
| **Advanced/Fatal Cancer** | Significant (HR 0.83, CI: 0.69-0.99) | Reduction strengthened (HR 0.75) when excluding the first two years of follow-up. |
| **Cardiovascular Events** | Null | No significant reduction in major adverse cardiovascular events (MACE). |
| **Autoimmune Disease** | Significant (22% reduction) | Effect increased to 39% in late trial phase, but vanished 2 years post-trial. |
| **Clinical Depression** | Null | No reduction in incidence; no change in PHQ-8 longitudinal mood scores. |

### Neurocognitive Health and Mood

The VITAL-DEP (Depression Endpoint Prevention) ancillary study rigorously tested the hypothesis that vitamin D and omega-3 supplementation could prevent late-life depression. Evaluating 18,353 adults utilizing the PHQ-8 mood scale over five years, the trial found no significant reduction in the risk of clinical depression or clinically relevant depressive symptoms [cite: 53, 54, 55]. The mean change in PHQ-8 scores between the intervention and placebo cohorts was negligible (0.03 points; p = 0.19) [cite: 55, 56]. Consequently, current clinical guidelines do not support vitamin D supplementation for the prophylaxis or treatment of psychiatric disorders [cite: 55, 56].

### Infectious Disease and COVID-19

Systematic reviews and meta-analyses, such as the updated comprehensive review by Jolliffe et al., confirm that daily vitamin D supplementation modestly but significantly reduces the risk of acute respiratory tract infections, primarily in individuals with profound baseline deficiency [cite: 6, 57]. 

During the COVID-19 pandemic, the VIVID (Vitamin D for COVID-19) mega-trial evaluated high-dose vitamin D3 (9,600 IU/day for two days, followed by 3,200 IU/day) versus placebo in newly diagnosed COVID-19 patients and their close contacts [cite: 58, 59]. The trial recorded no significant difference in symptom severity, healthcare utilization, or viral transmission over a four-week period [cite: 58, 59, 60]. However, secondary analyses noted a borderline significant signal: participants adhering strictly to the vitamin D regimen exhibited a slight reduction in persistent "Long COVID" symptoms at eight weeks post-infection (OR 0.78), suggesting potential utility in mitigating prolonged hyper-inflammatory states [cite: 58, 59, 60].

## Dosing Strategies and Toxicity Risks

The physiological impact of vitamin D is highly dependent on the chosen dosing regimen. The clinical paradigm has shifted sharply away from infrequent, massive doses toward lower, consistent daily administration.

### The Superiority of Daily Dosing

In clinical practice, "bolus" or "stoss" dosing—administering 50,000 to 100,000 IU once a month or quarterly—was widely adopted to maximize patient compliance [cite: 2, 10]. However, exhaustive analyses of RCTs reveal that bolus dosing is physiologically suboptimal and potentially deleterious. 

The 2024 Endocrine Society guidelines emphasize that the body processes vitamin D more effectively when delivered in smaller, daily amounts, which mirrors the continuous endogenous synthesis achieved through daily sun exposure [cite: 6, 10, 11]. Infrequent bolus doses generate extreme, nonphysiologic fluctuations in serum 25(OH)D concentrations. These sudden spikes trigger the rapid upregulation of the catabolic enzyme 24-hydroxylase (CYP24A1), which degrades active 1,25(OH)2D to prevent toxicity, effectively neutralizing the intended therapeutic effect [cite: 17, 22]. Furthermore, clinical trials demonstrate that massive intermittent bolus dosing is associated with an increased risk of severe falls and fractures in the elderly, whereas daily dosing consistently supports musculoskeletal health and reduces cancer mortality [cite: 2, 6, 22, 51, 61].

### Vitamin D2 vs. D3 Efficacy

Recent pharmacological meta-analyses have challenged the assumption that vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) are interchangeable. High-dose supplementation with vitamin D2 has been observed to paradoxically suppress circulating levels of endogenous vitamin D3 [cite: 62]. Because vitamin D3 exhibits superior bioavailability, a longer half-life, and greater efficacy in sustaining elevated 25(OH)D levels, it is overwhelmingly preferred in modern clinical interventions [cite: 17, 62].

### The Coimbra Protocol: Ultra-High Dose Controversies

At the extreme margin of supplementation practices is the experimental "Coimbra Protocol," developed to manage multiple sclerosis and other autoimmune conditions [cite: 63, 64]. Operating on the hypothesis that autoimmune pathology involves a systemic resistance to vitamin D, the protocol utilizes ultra-high daily doses ranging from 40,000 to 300,000 IU (approximately 1,000 IU per kg of body weight) to suppress immune aggression [cite: 63, 65, 66].

These doses vastly exceed the NAM UL of 4,000 IU/day, presenting extreme risks of hypercalcemia, renal impairment, and vascular calcification. To mitigate this, the protocol enforces stringent dietary mandates: complete elimination of dairy and calcium-enriched foods, alongside a minimum daily fluid intake of 2.5 liters to facilitate renal calcium excretion [cite: 63, 64, 65]. Recent observational data tracking 319 autoimmune patients on the protocol for up to 3.5 years found that, under strict adherence, patients maintained normal serum calcium and creatinine levels while fully suppressing PTH [cite: 65, 67]. Despite claims of high clinical efficacy in suppressing MS relapses, the protocol lacks validation from randomized, double-blind trials, and major medical organizations strongly advise against its use outside of tightly controlled research settings [cite: 64, 65].

## Research Funding and Publication Trends

The stark contrast between the optimistic observational data of the 2000s and the null results of the RCTs in the 2020s has forced a methodological reckoning in nutritional epidemiology. Many researchers assert that the strict application of pharmacological RCT designs to essential nutrients is inherently flawed [cite: 68].

Mega-trials like VITAL suffered from severe "healthy volunteer bias." The mean baseline 25(OH)D level in the VITAL cohort was approximately 30 ng/mL, representing a fully replete state [cite: 3, 69]. Supplementing a replete population yields negligible physiological benefit, predisposing the trial to a null result [cite: 3, 7, 52]. Furthermore, trials ethically permitted participants in the placebo group to take "background" supplements of up to 800 IU daily, severely diminishing the contrast between the intervention and control arms [cite: 5, 68].

### The Cycle of Funding and Publication

This sequence of high-profile null results has profoundly impacted institutional support. Data indicates a notable trajectory in the research landscape: following the surge of epidemiological optimism, annual NIH funding for vitamin D research peaked at $52.4 million in 2013. However, as massive RCTs failed to demonstrate sweeping primary endpoints, institutional support collapsed, falling to just $10.5 million by 2024. Academic publication volume naturally lagged behind this funding cycle, peaking at 6,019 publications in 2021 before experiencing a sharp decline to 4,896 publications by the end of 2024.

### Table 3: Trends in Vitamin D Research (Selected Years)

| Year | NIH Funding (USD Millions) | Annual Publication Volume |
| :--- | :--- | :--- |
| **1985** | N/A | 894 |
| **2008** | N/A | 2,263 |
| **2013** | $52.4 | N/A |
| **2021** | N/A | 6,019 (Peak) |
| **2024** | $10.5 | 4,896 |

### Systemic Bias in the Literature

Researchers must also navigate significant publication bias and methodological retractions within the existing literature. Audits of major systematic reviews have revealed substantial industry-funded biases, where trials sponsored by supplement manufacturers exhibited exaggerated benefits regarding skeletal muscle strength and fall prevention [cite: 25, 70, 71, 72, 73]. For example, a widely cited 2019 meta-analysis by Han et al. reporting massive strength benefits in athletes (Standardized Mean Difference of -0.75) was found to contain severe mathematical errors; subsequent re-analysis corrected the effect size to a statistically insignificant 0.18, effectively nullifying the original claims [cite: 71, 72]. 

## Who Actually Needs to Supplement?

Synthesizing the exhaustive evidence from the 2024 Endocrine Society guidelines, WHO fortification mandates, and robust RCT data, a clear clinical directive emerges regarding who genuinely requires vitamin D supplementation and at what dosage.

### The General Healthy Adult Population

For generally healthy, nonpregnant adults under the age of 75, there is no clinical justification for routine 25(OH)D blood testing or for taking high-dose "empiric" supplements [cite: 10, 14, 69, 74]. The consensus dictates that this demographic should rely on the Dietary Reference Intake (DRI) established by the NAM/IOM: 600 IU (15 mcg) daily for adults up to age 70, and 800 IU (20 mcg) daily for adults aged 71 to 74 [cite: 10, 11, 14, 74]. This requirement is typically met through casual, safe sun exposure, consumption of fatty fish (e.g., salmon, sardines), fortified dairy or plant milks, or a standard daily multivitamin [cite: 10, 17, 49, 74].

### Specific High-Risk Populations Requiring Empiric Supplementation

The 2024 Endocrine Society guidelines explicitly identify four demographics for which empiric supplementation (dosing above the DRI without prior blood testing) is clinically justified due to proven outcome-specific benefits [cite: 4, 6, 10, 14].

[image delta #2, 0 bytes]





1.  **Children and Adolescents (Ages 1 to 18 years):** 
    Empiric supplementation of 300 to 2,000 IU daily is recommended to prevent nutritional rickets and lower the risk of acute respiratory tract infections [cite: 6, 14, 75].
2.  **Older Adults (Ages 75 and older):** 
    Aging skin loses significant capacity to synthesize cholecalciferol from UVB exposure. Because this demographic faces elevated mortality rates from frailty and physical decline, daily empiric supplementation (ranging from 400 to 3,333 IU) is recommended to lower overall mortality risk [cite: 6, 10, 14].
3.  **Pregnant Individuals:** 
    Empiric supplementation of 600 to 5,000 IU daily is highly recommended during pregnancy. Clinical trials demonstrate this protocol significantly lowers the risk of severe obstetrical complications, including pre-eclampsia, preterm birth, small-for-gestational-age birth, and neonatal mortality [cite: 6, 10, 14, 22].
4.  **Adults with High-Risk Prediabetes:** 
    Vitamin D operates as a metabolic stabilizer by supporting insulin sensitivity and reducing pancreatic inflammation. In adults meeting the clinical criteria for prediabetes, high-dose daily empiric supplementation (trials evaluated doses between 842 and 7,543 IU daily) is advised to significantly reduce the progression to full-blown Type 2 diabetes mellitus [cite: 5, 6, 10, 11].

The era of positioning vitamin D as a universal prophylactic requiring constant serological monitoring has concluded. The field of preventive endocrinology has shifted toward precision nutrition. By abandoning arbitrary blood-level thresholds and focusing on consistent, low-dose, daily administration for specific high-risk populations, clinical practice can optimize patient safety, eliminate unnecessary healthcare expenditures, and deploy vitamin D precisely where it exerts its most potent, life-saving effects.

## Sources

1. [The New Vitamin D Standards: Understanding the 2024 Endocrine Society Guidelines](https://iaoth.com/article/the-new-vitamin-d-standards-understanding-the-2024-endocrine-society-guidelines/)
2. [PMC12103718](https://pmc.ncbi.nlm.nih.gov/articles/PMC12103718/)
3. [Medrxiv: Consistency between EFSA and NASEM guidelines](https://www.medrxiv.org/content/10.1101/2025.02.13.25322205v1.full.pdf)
4. [EFSA Dietary Reference Values](https://www.efsa.europa.eu/en/topics/topic/dietary-reference-values)
5. [Optimizing Vitamin D Levels in Switzerland](https://schw-aerztej.healthbooktimes.org/article/128372-optimizing-vitamin-d-levels-bridging-the-gap-between-theory-and-practice-for-optimal-health-in-switzerland)
6. [PMC9661368](https://pmc.ncbi.nlm.nih.gov/articles/PMC9661368/)
7. [ScienceDaily: Complexities of achieving optimal vitamin D status](https://www.sciencedaily.com/releases/2024/05/240502184351.htm)
8. [MDPI: Critical Appraisal of Endocrine Society Guideline](https://www.mdpi.com/2072-6643/18/9/1472)
9. [Medscape: Guideline Essentials 2024 Endocrine Society](https://reference.medscape.com/cc2/p10/guideline-essentials-2024-endocrine-society-recommendations-2024a1000ivm)
10. [Endocrine Society: Vitamin D for Prevention of Disease](https://www.endocrine.org/clinical-practice-guidelines/vitamin-d-for-prevention-of-disease)
11. [Vitamin D Insufficiency and Epistemic Humility](https://www.sochob.cl/web1/wp-content/uploads/2024/07/Vitamin-D-Insufficiency-and-Epistemic-Humility-An-Endocrine-Society-Guideline-Communication.pdf)
12. [Mayo Clinic: Vitamin D for the Prevention of Disease](https://mayoclinic.elsevierpure.com/en/publications/vitamin-d-for-the-prevention-of-disease-an-endocrine-society-clin/)
13. [PMC9460517](https://pmc.ncbi.nlm.nih.gov/articles/PMC9460517/)
14. [PubMed: VIVID Trial Results](https://pubmed.ncbi.nlm.nih.gov/41826107/)
15. [ScienceDaily: Vitamin D and COVID-19](https://www.sciencedaily.com/releases/2026/03/260315001845.htm)
16. [Mass General Brigham: Vitamin D Supplements and Long COVID](https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/vitamin-d-supplements-do-not-reduce-covid-severity-could-reduce-long-covid-risk)
17. [Medrxiv: Living Evidence Synthesis on Vitamin D and COVID-19](https://www.medrxiv.org/content/10.1101/2025.10.24.25338314v1.full-text)
18. [PMC11244154](https://pmc.ncbi.nlm.nih.gov/articles/PMC11244154/)
19. [Racial and Ancestral Disparities in Vitamin D Metabolism](https://digitalcommons.lmunet.edu/cgi/viewcontent.cgi?article=1019&context=dnpprojects)
20. [Melanin has a Small Inhibitory Effect on Cutaneous Vitamin D Synthesis](https://www.researchgate.net/publication/338179792_Melanin_has_a_Small_Inhibitory_Effect_on_Cutaneous_Vitamin_D_Synthesis_A_Comparison_of_Extreme_Phenotypes)
21. [PMC7676247](https://pmc.ncbi.nlm.nih.gov/articles/PMC7676247/)
22. [PMC3265693](https://pmc.ncbi.nlm.nih.gov/articles/PMC3265693/)
23. [PMC7089819](https://pmc.ncbi.nlm.nih.gov/articles/PMC7089819/)
24. [Cancer Network: VITAL Trial Suggests Vitamin D Supplementation Reduces Incidence of Advanced Cancer](https://www.cancernetwork.com/view/vital-trial-suggests-vitamin-d-supplementation-reduces-incidence-of-advanced-cancer)
25. [VITAL Signs Newsletter Fall 2024](https://www.vitalstudy.org/images/VITAL_Signs_19.pdf)
26. [PubMed: VITAL Trial Advanced Cancer Analysis](https://pubmed.ncbi.nlm.nih.gov/33206192/)
27. [ClinicalTrials.gov: VITAL Study](https://clinicaltrials.gov/study/NCT01169259)
28. [Medscape: Variation in Recommendations on Vitamin D Dose](https://reference.medscape.com/cc2/p10/guideline-essentials-2024-endocrine-society-recommendations-2024a1000ivm)
29. [PMC12103718 (Duplicate mapping)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12103718/)
30. [Vitamin D Dilemma: Comparing 2011 & 2024 Guidelines](https://www.pharmacy.umn.edu/vitamin-d-dilemma-comparing-2011-2024-vitamin-d-guidelines)
31. [Endocrine Society: Vitamin D for the Prevention of Disease 2024 PDF](https://www.endoweb.net/images/pdfs/VitaminDforthePreventionofDisease2024.pdf)
32. [EFSA Dietary Reference Values (Duplicate mapping)](https://www.efsa.europa.eu/en/topics/topic/dietary-reference-values)
33. [VITAL Signs Newsletter Issue 18](https://vitalstudy.org/images/VITAL_Signs_18.pdf)
34. [PMC5899680](https://pmc.ncbi.nlm.nih.gov/articles/PMC5899680/)
35. [ClinicalTrials: VITAL-DEP Sub-study](https://clinicaltrial.be/fr/details/12630?active_not_recruiting=1&completed=0&enrolling_by_invitation=1&not_yet_recruiting=0&only_eligible=0&only_recruiting=0&per_page=20&recruiting=1)
36. [2 Minute Medicine: Omega-3 and Depression in VITAL-DEP](https://www.2minutemedicine.com/omega-3-fatty-acid-supplements-did-not-reduce-depression-risk-in-adults-compared-to-placebo/)
37. [Effects of Vitamin D3 and Marine Omega-3 Fatty Acids on Depression](https://www.researchgate.net/publication/371866793_Effects_of_Vitamin_D3_and_Marine_Omega-3_Fatty_Acids_Supplementation_on_Indicated_and_Selective_Prevention_of_Depression_in_Older_Adults_Results_From_the_Clinical_Center_Sub-Cohort_of_the_VITamin_D_an)
38. [Harvard Nutrition Source: Industry Funded Research](https://nutritionsource.hsph.harvard.edu/industry-funded-research/)
39. [Townsend Letter: Vitamin D Scientific American Chimes In](https://townsendletter.com/vitamin-d-scientific-american-chimes-in-on-vital-as-research-money-vanishes/)
40. [TandF Online: Effects of Vitamin D3 Supplementation Meta-Analysis Letter](https://www.tandfonline.com/doi/full/10.1080/15502783.2024.2413668)
41. [PMC11459837](https://pmc.ncbi.nlm.nih.gov/articles/PMC11459837/)
42. [MDPI: Nutritional Rickets and Pregnancy Meta-Analyses](https://www.mdpi.com/2072-6643/18/9/1472)
43. [PMC12327616](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327616/)
44. [MDPI: Bioavailable Vitamin D and Epimers](https://www.mdpi.com/2072-6643/16/15/2388)
45. [Sleep Journal: Bioavailable vs Total 25(OH)D](https://academic.oup.com/sleep/article/38/8/1305/2417988)
46. [PMC7551674](https://pmc.ncbi.nlm.nih.gov/articles/PMC7551674/)
47. [TandF Online: Bioavailable vs Total 25(OH)D](https://www.tandfonline.com/doi/full/10.1080/15502783.2022.2046444)
48. [MDPI: Optimal Levels and Non-Skeletal Outcomes](https://www.mdpi.com/2072-6643/18/9/1472)
49. [PMC11767646](https://pmc.ncbi.nlm.nih.gov/articles/PMC11767646/)
50. [Controversies in Vitamin D Conference 2024](https://iris.unisr.it/retrieve/e7bcaf41-6269-42f5-8996-6175950c448c/Vit%20D%20consensus%202024.pdf)
51. [Vitamin D Evidence-Based Health Benefits and Recommendations](https://www.researchgate.net/publication/388000710_Vitamin_D_Evidence-Based_Health_Benefits_and_Recommendations_for_Population_Guidelines)
52. [Eurofins: Planned EU Maximum Levels for Vitamins](https://www.eurofins.de/food-analysis/food-news/food-testing-news/planned-eu-maximum-levels-for-vitamins-minerals-and-trace-elements/)
53. [Science Nutrition: Update of the Upper Tolerable Levels in the EU](https://science-nutrition.com/en/2025/01/15/update-of-the-upper-tolerable-levels-uls-of-vitamins-and-minerals-in-the-eu/)
54. [EFSA UL Summary Report](https://www.efsa.europa.eu/sites/default/files/2024-05/ul-summary-report.pdf)
55. [EFSA Dietary Reference Values (Duplicate)](https://www.efsa.europa.eu/en/topics/topic/dietary-reference-values)
56. [PMC10407748](https://pmc.ncbi.nlm.nih.gov/articles/PMC10407748/)
57. [MDPI: Vitamin D Binding Protein and African Americans](https://www.mdpi.com/2072-6643/13/2/499)
58. [Free 25-Hydroxyvitamin D and Impact of Vitamin D Binding Protein](https://scispace.com/pdf/free-25-hydroxyvitamin-d-impact-of-vitamin-d-binding-protein-3hsrk8ya7d.pdf)
59. [Lirias: Polyclonal vs Monoclonal DBP Assays](https://lirias.kuleuven.be/retrieve/33ebb929-6806-48fe-88dd-bf08b53670c6)
60. [PMC4165606](https://pmc.ncbi.nlm.nih.gov/articles/PMC4165606/)
61. [PMC4030388](https://pmc.ncbi.nlm.nih.gov/articles/PMC4030388/)
62. [PMC12103718 (Duplicate)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12103718/)
63. [Vitamin D Dilemma (Duplicate)](https://www.pharmacy.umn.edu/vitamin-d-dilemma-comparing-2011-2024-vitamin-d-guidelines)
64. [Endocrine Society Press Release: Healthy Adults Take RDA](https://www.endocrine.org/news-and-advocacy/news-room/2024/endocrine-society-recommends-healthy-adults-take-the-recommended-daily-allowance-of-vitamin-d)
65. [Harvard Health: New Guidelines for Vitamin D Testing](https://www.health.harvard.edu/healthy-aging-and-longevity/new-guidelines-released-for-vitamin-d-testing-and-supplementation)
66. [PMC12447537](https://pmc.ncbi.nlm.nih.gov/articles/PMC12447537/)
67. [TandF Online: Industry Funded Meta-Analysis Critique](https://www.tandfonline.com/doi/full/10.1080/03036758.2024.2325004)
68. [UK Parliament Written Evidence: Industry Funding](https://committees.parliament.uk/writtenevidence/130662/html/)
69. [GrassrootsHealth: RCTs and the Foundational Flaw of Modern Medicine](https://www.grassrootshealth.net/rcts-the-foundational-flaw-of-modern-medicine/)
70. [Medrxiv: Mega-Trials Meta-Analysis](https://www.medrxiv.org/content/10.1101/2024.05.09.24307122v1.full.pdf)
71. [VitaminDWiki: Coimbra Protocol is Safe](https://vitamindwiki.com/pages/coimbra-protocol-using-high-dose-vitamin-d-is-safe/)
72. [Coimbra Protocol General Information](http://coimbraprotocols.com/general-information)
73. [Overcoming MS: Coimbra Protocol](https://overcomingms.org/program/sunlight-vitamin-d/coimbra-protocol)
74. [PMC9033096](https://pmc.ncbi.nlm.nih.gov/articles/PMC9033096/)
75. [GrassrootsHealth: Dr. Coimbra's Protocol for Multiple Sclerosis](https://www.grassrootshealth.net/blog/dr-coimbras-protocol-multiple-sclerosis/)
76. [NATAP: IOF Vitamin D Recommendations](https://www.natap.org/2010/HIV/072310_01.htm)
77. [Osteoporosis Foundation: Vitamin D Recommendations](https://www.osteoporosis.foundation/vitamin-d-recommendations)
78. [IOF Position Statement for Older Adults](https://www.researchgate.net/publication/43346343_IOF_position_statement_Vitamin_D_recommendations_for_older_adults)
79. [PMC11836767](https://pmc.ncbi.nlm.nih.gov/articles/PMC11836767/)
80. [Osteoporosis Foundation: Prevention via Vitamin D](https://www.osteoporosis.foundation/patients/prevention/vitamin-d)
81. [Scispace: Vitamin D Binding Protein NEJM Critique](https://scispace.com/pdf/vitamin-d-binding-protein-and-vitamin-d-in-blacks-and-whites-4njtkaaqkg.pdf)
82. [PMC4165606 (Duplicate)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4165606/)
83. [American College of Cardiology: Vitamin D Binding Protein Journal Scan](https://www.acc.org/latest-in-cardiology/journal-scans/2013/11/20/23/21/vitamin-d-binding-protein-and-vitamin-d-status-of-black-americans)
84. [Kidney News: NEJM VDBP Analysis](https://www.kidneynews.org/view/journals/kidney-news/6/1/article-p8_10.xml)
85. [Escholarship: Powe et al. NEJM Publication](https://escholarship.org/content/qt7wn9815v/qt7wn9815v.pdf)
86. [GrassrootsHealth: Scientists Call to D*action](https://www.grassrootshealth.net/scientists-call-daction-public-health-2024/)
87. [PMC12103718 (Duplicate)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12103718/)
88. [NIH Office of Dietary Supplements: Vitamin D Fact Sheet](https://ods.od.nih.gov/factsheets/VITAMIND/HealthProfessional/)
89. [PMC12029153](https://pmc.ncbi.nlm.nih.gov/articles/PMC12029153/)
90. [Endocrine Society: Vitamin D for Prevention of Disease (Duplicate)](https://www.endocrine.org/clinical-practice-guidelines/vitamin-d-for-prevention-of-disease)
91. [WHO Guideline on Fortification of Edible Oils](https://www.who.int/publications/i/item/9789240115101)
92. [WHO: Launch of Guideline on Fortification](https://www.who.int/news-room/events/detail/2025/11/17/default-calendar/launch-of-who-guideline-on-fortification-of-edible-oils-and-fats-with-vitamins-a-and-d-for-public-health)
93. [RheumNow: Best of 2025 Vitamin D Prevention](https://rheumnow.com/news/best-2025-vitamin-d-prevention-disease)
94. [ADLM: Vitamin D Testing Clinical Implementations](https://myadlm.org/science-and-research/scientific-shorts/2025/vitamin-d-testing-clinical-implementations-for-laboratory-practice)
95. [Oxford Academic: Testing Populations at Risk](https://academic.oup.com/edrv/article/45/5/625/7659127)
96. [MDPI: Empiric Vitamin D Supplementation](https://www.mdpi.com/2072-6643/18/9/1472)
97. [PMC12103718 (Duplicate)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12103718/)
98. [Endocrine Society: Vitamin D for Prevention of Disease (Duplicate)](https://www.endocrine.org/clinical-practice-guidelines/vitamin-d-for-prevention-of-disease)
99. [Conexiant: 2024 Vitamin D Guidelines Critical Review](https://conexiant.com/endocrinology/articles/2024-vitamin-d-guidelines-a-critical-review/)
100. [Vitamin D: What Do We Know By 2024?](https://www.researchgate.net/publication/386544071_Vitamin_D_What_do_we_know_by_2024_A_review_of_the_evidence_on_the_effects_of_vitamin_D_supplementation_on_the_human_body)
101. [SciTechDaily: Popular Vitamin D Supplement Negative Effect](https://scitechdaily.com/popular-vitamin-d-supplement-has-previously-unknown-negative-effect-study-finds/)
102. [PMC12303150](https://pmc.ncbi.nlm.nih.gov/articles/PMC12303150/)

**Sources:**
1. [medrxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEo45sxPtPeFbMoa0HHI-hXSiLUCiYB-XYxYVl_xWg9pYNOsScHTu1J8mmtloAxTLFJyG3T8dBNmYjorKemQZx2vsX6Hh-qHowuyItRmq1W9qLz4f1QMVA3fuhbGSSTQyBGAMLeBUeT0dSmk9mrr6AoPHo5czIK0PUHowBP)
2. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFxWMU_dDbCoKElV-3oMmWAR5l-sOs50FPrqLammq2KFO-GVbHAs3E4WUrSw_6LI8Gu7MZlDwQayvHpss3pyB_lDFTFMLY6SzW3ZeeqAnH5vOfvy9YEfXIvq2eZip28glXQ5JMhqYk=)
3. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHEppHXOrLodIJUtr9ZNeEoXFGI-x5OwqnfWE7nNxEedbRmGgr76jF7amusJVllqhYSWksgPdL1TiahOh0Y3SJLxm8b9K9111qyZQ2KG-RLwNO5GiurlaHVAUltBjWCCct4QaP4_Hgk)
4. [elsevierpure.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF1qrPznUTEM49AV6tG9dszLL-JBUUDj1ybD-uQbKQQj0RFX4YP71c55agXrKSiC97EQBh6LJBbX2Gjo4eu4nuhkY6Bv4wq-5W8QtlkRrBr0TzBtJpPn0m1hYOY3P8YGQqf3ZWJIptSoaivpIMW7iMtdv838dlByDCKHdlqn_Shk0x3giLREFBPpMi3YEdKryY1Kh0w-0JK1DcZWzv0hrXZMbl8iY-0Z3hkm7w=)
5. [endoweb.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGhcmlukox7fOFQiU3Cs2ZF8uV2O_EaghK6f_Gi56lnzv6ZOBPo0v4MbeFa60nWrrKBGOisZwzs8n6CimU5mzkKve5RExwZI0ASJhuw9TVwgpgGYzkuQUdpS-BWUy2wD-9mdlqcjYSMMR0N3iQ4-PCtFhJckK9F4Si3VYbIsDoRylY2)
6. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHntFSiv-lJpHBDp5H_oYPv9aC5En-EShHczVB1atHVHNj-f6L6FtH8-dmBQ32j6BYSIffG7v1GC1mzGcuPfF5E571JPXqJq2ni77Fo4kypOoOo9a-feAa9BzRy4o4=)
7. [unisr.it](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQENOmbU_pqWDc_tdT3FxDpVy7TWoWbjWMrWM3HKoHl0hTZW6Oy7hfvD5mfdqvG4Ldp0XPoNLrWed9ECY2X-l-ZhWavn6HXbgSbtwQbabyp5Qg1xbeOYLqKOVmIxWXb74m443TKv5JT793_nmbdHgJEwPnskhrX2sYAm82C4BHachdUSVIfz4O8o9RFTkTZ1eivSN0KVQpqw)
8. [myadlm.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEpxf_AZYXQSiNAFZOiwAymQHrMEq6xfZqT83P1BZnN8oEH-kr_LI6JPDxkujoazs2foan_lSRexZ4VScwwqUvn9IR5pXco7-Fm1f_sA61JN6iAq_ZK1ecYTvQzVheTkWA709zArECb9MYV8gX41oIOaifPtvcsFZHs7FX5AALjiFGban4Ji4QyBbT2XBG38uGmFP3GfjD45CCXLxd_BA1Yx8Hu9xLsgHsQAI1PtGTg_ceiR2ThLY0=)
9. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH6WGZev0GJXdkr_dPQ60xXu0OVwF7yYXAY1Q2TjbTYlzK-Py7HRnkHGQHy-zhSiEcU6u41ICHcDOMYnC2YzG4AvYg69Xs50vUt92G0jwFkHf2aWW3MnB0dWyCFsaQ8W-yEsPZTZ4k=)
10. [iaoth.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQECtXms6fLrpnE5f_8cx29e-EhyHbp53k5ROcpysI-VBCcfZm1WwB3TYjCGd89DowdaRKpoAz-iL6Xx3hGhzY3i12VnbpxiE3At-3iAFCPOpStqSHaV_VW-6UxgIpm25tbrKctQ3zl2diP7KhJMhUBupPMEYEjrunuNZ9mZLHDWLeS1rYi9zg1-Q17Q-FhbXT2Y8yHZ1VqLmZfZQcddVKo=)
11. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG_X9YrR0Q8GiXTWB9SzRvh9B0OMqJPfDn9wUEPf3g94J0a7ySubEMTA5Kh0xWWJXDySOvEC_iavqjY0WG9h1a7kZVwWynfBXF04BtNwX7h3L158nPlAkQwHwO2Lp0SFIElqLCIz8ye)
12. [sochob.cl](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFrIJ53xkN1kJ98H2HAJAlAcbDqYErtcsemmVWlnJ-5qq9DO209QI_HJfF-QTEGL6tcOLaKLqFgcSZMKWSG_ET9-DHXPA993-Nh_wjyu9YWpX4wkWR3cbTjvQPZ11nZsDJvN5jAR0lLcWpbQrXBCZ2U7DyFr5Sktq3Batnf0YjPnYo4Crxvj_ZmWOK4Z8vyReFhm7gUL0We9W5D65DWPo_WEggdLl5XuUrTWmRpWdPmZISk7AyboZCOJTjCnkO5DZAw5wuohb3neJ9KDg==)
13. [endocrine.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcMwumyISDZbOhHCGsEaw-NpguKMi_wm9i2sTbSDPtA660V0bVgEBqQiDPyzVODxx_ITgHawlx10WGoJ6j1SXMGKiarXczv8iKWPceuP1g1Py-iodHCjdg5sF79HWyi1Zd1BpvIfNianU4FRJwNj7pmRoOn7-wP2VKCNosjZWY496g5c5wdR8JzxH3MEB_HA==)
14. [medscape.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfWqDaqncVHXR5aWz4a9866F-__zqHBNUdepVsEZ60iiVH-PNc6qm2QjHUO-1SNTYMTNA5ja0TRZ_EaXHmAgGeT6K3F3D4I7fkgPSMm_j-Tyu5Kj583qo_SDr5d_ZmU3RuXyzvsHx5HAnOa1zKVQzfm3J13JAXULzQp0ftcwoa3iOi7r_DyPzPrMPg0Z1jD3iBkDnbBxMbt1p-sKd6w4BZAzT2UA==)
15. [healthbooktimes.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEIa3ovgHSO34ITPdn2w9CFstSvDXuVz3Gt2yCF98YgjCbY23b_h3ng2dxeANvCQvg0cgpmMbpgANYggY8sK05qMh_ulLHgXpNHzl5pL1xHZ1i8JgCQMqsEWS_VPdEEM6_7pQ4rj_Fv57AdQGI-vEGLj4trSk3QJqtvTMYpUEe_EMMamLwPXEDdyaCIpAGizn6-HNJrKAj7U6m4yD1b2HwaUtvZb_A5NnDY9n8akWFb_G7WFB15XAGIGTiCuE0sUshi8F2epBPHJS0YiTxe0uczrAtuo-EDOjU=)
16. [sciencedaily.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGGZyEbMMgeZKkU6hu3H5iUF8KMOEVsIj5kcM7mE1kUZ5hpI3tE8p_fEteF83nfgih8VTz95kqLoHKJ067OlC09Z1QY-T2kzyPxLHCwhIL-8FVgAkVH6kwm08MFoGfkF_GiJWVQIOAv7v0jg1zijQpolq3A)
17. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHznOcM7Ep0n08aHSuxDngN-ZTRthVqRVQ_MLwlOplP5hs_lui2cngEP4NzuB-te4wM6jHY7leBvxhtIe3hsWoKh3Skwt9_PFXEXA94n6Y5GEnI3H8ij9gKoPsaY2_HTH0_z1jw9LQ=)
18. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHL-SeusNj2u_vrxmpnlC5iubuYX942NqNVztty6yLgtnLv_d4ulPWo5C_OXPPKFK_pRDw4NKKuD38VaXkG4Fy6KhL1XD_8VO-tcAzjyP_xEKm2zGjWQaKJhQWvnFXAtd2wLnbQ4eY=)
19. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEC7hUrqNd8aw2Hrm3bL6pQtuTI4epJRdGLcQ8aqlewSRuQ0WW_0VW0IetoCRd1xZvrBp16cMLAiXNNC9bIOknD25fYQJvBp8ZjYvbGXwMPlYGe-ATbNL74R9iaBT_OQCCGhEY0H93_)
20. [lmunet.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEI-8S8xusI8He9uBJRHqawvgTfEgk3N6BemejI4iBQqdo6gCesFpteGZLBNirCAz7SAD1B5n2J3RJp08XIyZ-8GsOilWPe6aiB-6qR4kljEIsYZ1zT394-VC9tTCjOqNZXWWiysOLNEXQMtJbh6uBSM77Ck7coiu0Gp5YvudmYRU5B6vot9PwlSv9s)
21. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEPYdEUT1yLWKP811hWHJkF081xVSyuvgvin6eZAKG_mmeVaQMBGtGBhdAoisB-kWomhYA9KtKQokEF7FrB9LEH18fLQuj4aTUoXVEaMMNXMeI1XVqo6qGae9UDVqdqdvvRB1iPZC3almvC9JjyZC1Ms_-AXEOvZfwtpRtAYMZ16rMGc6nd35xYbrIBCtDx13PHuA4xUFejDyap_vWprKK2FuXs4asOjSeX-W_NP4QuxbR_wcGSbBjPd-TAKFOrgKE4Fd-YfsmovjGapc6_QSCt0Bk=)
22. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHU4ARI6suoswuV025h0FzhK79KctqFglpEmBgHQ8eH8s55_3pjhmGVpB0v-UE80jIFOSddLmAPNZ76hF_7m8-l_sZ3CUsLSOKiQ-c3XFxctbiPJLWSwaQnuVygJPMZ)
23. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGV8RD1FYX1KlPPAg3CFeU_M6BKFqKzbaNSCS1YLVE6fVIR1vNg49pj5Me4UeF6LMzwHcKf77_eQvaxLj7KodMK5j8TslMJbwq-oo2q-WbN7ZiT98_I2GN-KqFFVPDJFsiEOM_d6kE=)
24. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGyRr1SAywyo5Eh-FFSzG55p8ZFVuDJwVWSj13BpM55WSvmqXfnKdK73AA35bA3e-BbN3-EoLHoW5e5h78gIz4oJ4IiMeIwj4KAhrNQ6_Bg05zdnWSiXqnpBMuqngoOnrPBrVouz9pNd1QTNSLSQUDfpeyq)
25. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHjXJDAnCEpSAgn2WICbwxCl8Ce2qtSv3yTNjlQpJ5GmToajnAh_WLpIAYVfqvC9iOqy5j0o5rbtA2ejMlWBBz1IhabvSeK9v_SRAr6uxV0TvXIQXVFyDlDZQ8kw8rlB5jRzFwXs0mU)
26. [natap.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHH8n0YvsZLRZ7IxXFgodGHo0ArZ4R2U4sReaJoRijorO-kr4LY0xn1vZEYxZ1ahzsRUw7FojtSHjOqpXiH4Xf5lPIr0aDLfpt-7rTBsy14vdjKV2BmSe1pcflg8a1ukfMN)
27. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEtz1RuRNjBxf8m-wcBuSAD4M9kJ6cLDHA3uLOTzJNSh060Gz3q1NvTirjTgwVoirUoXYenU40KU0-7DRtTcF2aKyKde4qzsOSvyD2YO7bBo3GART2rJh9LCShAWpu_SfWExQudhXre)
28. [umn.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQECEZgfOxlkWPI9QYoJDdK03Y0KQdXYzjoajSr1chOlgZmW5r8x7g_Z6k-1lSGXnT0ZFEf5mpSWm-oVWXU-7o2XCrW2jYO55ilTSE63bXeXkr6hFGrqCx2mWMPHDTeJaxex0aey13a_9RNSXFLYzuvqyISIu5b_rdMTsmJTa5CMFS4EICVicFGEx09Wmw==)
29. [osteoporosis.foundation](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF7XC6QERLeW0vWNF5QdWqZfZuIWVKDeab4OuYWO0gJj-5JItTvpjccZncxIjE9udwBciW6bNhCu9dbNv7HBC6EYZl-iUJJlTIeejbpTOQCkW8r2QRT9B_0OVuWMmO3ZyKQK-Q8m-id-1eAQE0XZg5sp0Y=)
30. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHa-1-ZI7z3VwxU3S2zF3jWtee84JBio9ORIP4gklkg1EideREmea5vAHsKAq1XhcW9GPyhQs7Td8JgY6Z5g8AHW8VlJPnSlA0sUD596LDy1ha4nWsxISVAlxMz3YG1Y-XxcX7tuBs3m7NXfrDT8xM9Q0bkHRwcDC6s258SLXb6SuxMINzlfkkWXSE7R3aiCMnPQcx0bpkdHZm12-IFbeJtvDUJZPccTWo=)
31. [europa.eu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKh2Sa2PfzqnqpQv-htGTwxHReAPobGBx-fwDd7L34N-18K8Tb47B4lhnTtWcGkr4i_kni0_cLYPp8TXaIeZh31F1hwEkhaUkBXI5N83X0ZZn-9GS3dqBtaD73_8gWsIG1DMyWMT5nquTRCt09s86kgyVLCiFXiSYITZPCgP8r2C0=)
32. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeaUPmkCt_RuS-NO37fxH5rIiNLEg3rLfuioHqEu0I8spHGxNfi3YOBUV2wgAVsZQTVcXZnj37L5rMT_SLEsu1-C-Om7QmURkeQ047hc6GPR1XW5k2MPB7d9XoAAU3hdwPfkYoLdKm)
33. [europa.eu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEYgmJ3LdJf-eusXLZyKWvsXN47eIy94BPfCBTunAKeQH-xP-Np7TLfIbbs8f5dC2ZeA9Yczgyxctqq3TgCuGaxiDC7UKgJf-HU5cSAOtcUPoEIBSiUwCUKioVADNcQigGqfYQLrJR1ApBac3_6U3-uid-PTp-ar98=)
34. [eurofins.de](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpLMf27ofdcTTiOwTlbJKFupBPfPk56GXiKWWK9kbZyTmPsEqo5BNVp3ZwEs79SakVnSNHZOp2QuSHwA013Kc8OL-SaeONXEJJVbj4a73wOlYmF_Sad2vKO6Ir7h5PhaaSpE7GIf0ZFbJqcbJscSqWaiHw9vea87zi6Rw67liPk-JesfcK-eaVUYqdgHYmi_rgogdkrh7eCmvkT6qIMdK9maYSRKSdNA6hFYYYG2y0NZdijXRp0XL0gc_K)
35. [science-nutrition.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHf48cVoP4-CsGe3j_k1c2rCsd9A1YtAiMMKeuyayZM6wDUdsTN852coa1TAmvFIZtYwsV_tpPBkcpzOTFYCcdQ1HFg_t8ooatltuNcOKYLClf7vrzyv6IzsQenm6mC5zfq1OioMQFl-OQViPpSZ1XlZXlKTcciZju3ONctj_ZicFkyxdSzLQZYahQXDxLShqLsOVqXmI8HEb0vLi2L7x7bCt9h9bdS3DqlpMuI5g==)
36. [who.int](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGLhctXWpveLlQNmxCmZvObYuZ4o53z7u55dyiYOl2TfYvxTLJ9cdlBujvqxzMS69hVXfS6FsgQpXnUTBPI8q7Gb277MvJrep9BLHwereSSHrCW-h4kKY39E5sLEtnluPPYSAVj6i79bgu9)
37. [who.int](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEjeNM5eWR1eCr0oosClk8zXqbFWtGBFGqVcCyutAVpwRPDuKBJIfSEZU0IvigVYcNtChDaTwvoJFrewNyQZhNwZe20q6XWxO1DFdYZmURLF2s4lDC7Y9X4sDrLi-ku3zQ5aeH4r9EntlO3fQSUKH5lb9cAeDaMtDiiOH5adl1D_M1JNQjNycvmp-9FKB1Nocss6dS4UaydQMJXpIxHqHOUSvnOATD056tkxpxbaZvX7ZbB-c2F4s-XDR4qBrLI3tS_7uh-NW_S34RJizjP_PKLYNOALfaIh8z6WIed9ckH7uqxjEg_jg==)
38. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGsRkn8lkxGr_BxxEfKXcwDqZEUVgC4E7gqkWxB8huR8j2dyJ3kOLFJE0mkbsDZoLtcf6DdrtGer1VE5xehZAqSkD789t8nG6wdZ444r5LC6dFsIyDSQLFfAxL7Yw==)
39. [kidneynews.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE8TFz17SNuTm-5lr0ueiCBjf7TmbmZhPvOwiBaTSGoXK7dj0u-E9yS6ISFhBwsz-qrcDgaoR6vvDFnERq2tPZsRWhFY6sCrGuqqh1f9qomTiGZtxYtMVbz4yDYOAWynhAyn9_6Ls6NerfngZ--FlYKqgLFanXxn2q4XUdTf5oA)
40. [scispace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGbmZ56k90JKLjBsxGG3iMQouvXu0kSOZ2GbZcMghkdcNh8UBvYG31uubTi7aLYK434HWOw_PsuyJFypG-I8fNlZ5CxZ9ohB2ZyIygxJvGZZ1l6KmkUDr5jE_WwqH9DNrDrdQa7C_mkFz2aieBIOUE7WfnAHSsFOTaR6jWw-lWFVUEteZnxsf6Oyv4CrGdicE_59lPxuP0GVrs=)
41. [acc.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHTvHFwCHh8C0vrTcTtUqQIwqlB6o9Yt7hAYbrSn48nnPfHKAE7VCqPnvCNsIvnl5DXXB_3hEOSYYO-cfPLsa38lZwG1C_kS2jU28gNOISkZ9WJn5z1cqCXgXcGeYIjuFJlEDflOwKqa-BZCmpeXyNnB4CBm6MMlW0adgfNuMFQxGUk5vLNCVLPH-WJmBkaOWzVme0NVLJKeqTlN8Emtpizzb7QYyRiFB2K0WAJpX-LjC36bodfAwRKV6F7cgsoFA==)
42. [escholarship.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEBM6Hk4Ouy9XgieWLBLp5ojJQBaMXxAx1K83exnG3bE4za0Vg8t_W8d5wmy-rHSxKmG_gDmbfayidSWcJEeq3Rh58YAr_fcanfHttrDgFTk-V6UmbPgeozZP4-2pG-LBz2vC72z1R52mYKhu9RRP0=)
43. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFULHR3LA43TkLrsagyEoCm6K_w4YAreUx2-cWQatZ0iOfvegw9dXX3TACZwXa0NZXSLIWCw1YTKndLjHugfmKbsA_7TT4G7Lf5XaY5S6Lgv2l1xfF7hwsDtYJLelk3-yM7fAGguvQ=)
44. [scispace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFFlM5qXH3xS9ZfobdDVNLkIz6VGjYW5I3JfcMCGD03NpYDFkyC9IWeW0cF1sJobhPxKkbeFA9TwoSr2tv2ZGFkjoRYJMEwrGfm4ou3MmnoS1xFfy0PPaOXgRDE93eButnxZyiKw5-ZvI4GRmH6IHPsBIudemBWJ3pa_5OwBB39Am079SpVHMUiEEZGuvkuBRBMrATdyQyrxpw=)
45. [kuleuven.be](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXzk8DE-nntYcgofc2Y91DLOdz86LY780G_VGxu0pWcVazYcafVuuFwAj1tjdPDRhu6vhxFRDS0ZT6MGP2Izf9C7Tz4SeyNcti5-A4vSXiqfZBwkiTYDKzGaHUgr7nW9hXp6OKSec4wv-CW16NuUhvv2daUie0XVeXu8xAcg==)
46. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFDkVOwOqWfH9zg3_7sEcerL1C9Go9J56S2y1Z3DB2XFsVYKgustyin_M0y3lNWfLVVLVf6Sx6H4-Tcvvo7v4CIgyi1rHsAibUNvMr-x0kbORKme8IzQ72omBjixDEWqEJu_HNsh44t)
47. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGAX8u5GEbRgq6zoRvKM-d63Q9XpNb25jCl01IBGDF1qHOBy3HL2RhSkvk9VBizRqmdKqfjjfkLcwpSWUdwANHxoe-0V7qwWZro6OaA9D2rntoaHr9Pfy4laAN4x0sD)
48. [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFFPCS8QvFhAyCUHVS0oH-SIWwzY9sFEu4ExYD978FtxO1XlNebct-kR7HhNKeW6DQjj2dC2NRRhgydRfS0ZYtMaGJ56BmnBkgQgsPzwJd62T8kD-3jOPFAaA1L7-BcHAxa)
49. [osteoporosis.foundation](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE385e_vhcNxhpGEl164TKxTdo47qklKyAzIV1T8pHUVRrfL1BbJZYc2kDKED2HE4QANKBB1_4e20hM3cNVQ1N0_Emvaxy4lXuCqflLy3BYmOJQlcMTzIzjBHpI0bhmZr8eqo5j6EGsabP5Ox4Wnm5HHWTHCMyn)
50. [cancernetwork.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFsKGtJQ6LaxWzxdWbmAPz_51IAS2GiAoHoHAhlY01mEPt8l3Nsu2Du6YE3kS4q8P5_n7ldsDionuVaEd2j4nUwMI6cIpHWiD09caAKih-4pjc1jIkEtA_0Wb0kgO9Pv66iO0hfIzFhThJpFEGQyiK7gABXTEw4RAIJc93PRIJAVq2QR6FIjnxoId0jf-sr9mtek2JXX-ecE2VxVZjET4xXX6d_X9vvHFLH0Y=)
51. [vitalstudy.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH3lD76RmhsoULlcYksNMWvKEMLQoXJUa7g4cndR93_MkZc-XFe2x_ui2dSLrVRyzpWhjVz-YYi9m4Q7KjPH-Rngrk8j1HMrSnB0L0wqmRM1--jtV17C-mLDP8z1v6b347Hq0X9Qa5I8qk=)
52. [conexiant.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEQI4va-biPgc9wPiwf10H1E2xA3wU9q_4mAowMMF-fzFUO3mdDrPS4es8YhcjaJqx8Or4Go95dJNU1d_DHpZPI3mL8H443ycSQheOEO5AyYUgB8BCQPEptI3_R45JAv9nIBuCpioDmoaa4Z4k6_AwYYyCMOyPevONJG-80SByJGEKoQjC7AGxeraWt4jBE)
53. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHAviuSthPE7Xdaw3J5YBw0E7fcZ-v4cBsDq9JauuYBmckK-3Eziw_r-ioIXaVk_hcYYfxPun-EXdbNfUrXx_tgLuGR5wXwHrkDCJip6g7gZvmCTrGSNWmxDdwV-1iTacscxYJH_-o=)
54. [clinicaltrial.be](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG2Wg4QFQ27hKmV0YnT-zAYtwg2SKqUupjIkNGjpEe2zYpEjOAJNvpsb9VzsD-9Hv8_wCarqGJUm9wygiS8ESRxqayueVCAfeLlGZl8kPxHzQS7KNdN-p5Cb3wi7wM0h74gCgoWVhlD27gMdVV4b2L3xzZg5Agqn-EVjryihMi2L0SjBI33c2p-rlYH5lDaDQIL74_Lwwtyi_gjsB5ey-sxqm3hE9v4G20NyucvDdkOK6YRvOJhYgnpqnTUtylhq6AshmIlwhcRLFUFaYlrKEC9g6pdnef88Ri3-xYS_Qi16-C889xoEcPU8YZoZtI=)
55. [2minutemedicine.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHRZjON7705B0fsUTysPCYY1RZK_jQ6SAZO4gkQeYo9-CcvexiQMPnQ3C3nq775ddGdoDK2zGpdb48RMlMRd_rLg2MmxfjDmkrMtGKOfkk1w23i_E5FUFEcDawTyGKhTVKdy-Jr7o_ki82_op-tCddnxpVaiUUpCD9OMnKUtAZXDCp4gCpX2b3hnim0Imgd5jOXXIQ7JMj8I7PdgQ5pUxSHZP4CH_dtPypjcg-NWDycv1U=)
56. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEOEVR_DwU4gHCjXromjO3X547pEcapCwQmT8u8Y8nkc3wttl1K34b5DfVDfGc551HHilwwsASf16ANMOi7S16A87lgJBaNE9_bZgHsaQmx18NHY-GMSlqBQ8XFrKR8WzKGsiNTOGPdmEpYCAVF8ltpwv8x9Co8AjWYfGrBymGHtx-QFBSxIrQDIt7Ry4vAOJvqENmv5ty2FLO8geYiahgaehABwyuub-S-vvEKfno3avldpkV4G7rhezeJwjY2rB1O7dye0dfdxZ4iFmmifLs78SBrftcS3WSnEVIiFIfZzSvNUa36CDUqvrf75kJyps6VNnZyq3JAMPRfpXvGTiFKeDefWiIdjB9diWOZ7p3LUYmipMR-nsNvpScYC44cDgTP7xdLIZwmj6CqRUU6p_9FqQ==)
57. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqOWGzEYDw0Ps8EYmX5WBA4zBL0AcvNNkgzLpe4rDoppz5mZGjjDTuBFnXAylqSPNZ7BkQPlkGP44o-o1JCZGm1Rp-YLuLoEe85TRfnoBeLwT21o4oh1ru2-A0NxumsXEf-EwBUso=)
58. [sciencedaily.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFsG6DIqRwxvhJ-H9QyNGR4wXJo4uxC6vWMNfb2vJti0bYXTmbIpGaf__w1ihcP8lb9YVCwM4ytDKDyLn8-GNKcESscsDoXO_gxTOvAMYmMJahfsNHpeik2yxRMNaYkvOOIbA_3ZAtWQ-uwUbhsjBiiNNMf)
59. [massgeneralbrigham.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFVDDRJodi_pvc-Oyz1MqgE_qv4Ec6nxVcjkOBnWzelzEIfFPwwZiuo7AfZlSTyk8ZlbuKVpR_0_qc88A0B0kTZ3BNwC8x61KOK9bhtXTX_dNmYkTS7jo0v1rV4GaMa_8zdR8BrYJHVMEKi48OpfjBULd_3uWyLcopKM7OCWH8u_PCslUJz9Ox6gMHdzioEbiwOmoeI9Fq8UR7gfBquK8e87X3BDNYxiCW5I99qIHbRZq7X1XBJbWWS6nrLtRqSv0zehY_11C7z1vg=)
60. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIAY6VTkQX-CpjkMmykIcwCO-zQcmJK6k_splDIq-gmDzmEIFklfYonxUdwO82aOsaNYeDvr0_IZFh03TwUG_grGSNjTxZLRrcH15Ve2Rva7SyizjPqSGGnFRAbarL)
61. [vitalstudy.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH5lQYDejA2PlVLySScfZ6NJi2owTKPH7pPBGwwasqP2nSETsPDeLM-3AFD_S__qozpRiKdFN4_uE0TYRpbv-eYJB_sgQwASBZGvMrgKEbavbQ8vcL3CYKJmksMlb8es8F-rC_4Dw==)
62. [scitechdaily.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEaWbeOH29YeyofSydrjN4TCwYZgUtgIPiDZkdRrBi0RZCqrwCW1uSiREqSsniQN4NKFurQ6z0GlY2x8ZpKWrwDWwU_zDgk7geO08DebV_WjYG6zMWNaIC-sZOO4Qg7KDrIe2MMyNOk4gHSDJACt2E7a94nv4OmdObULB5v6dLjRRYTSC7PKqGJB3thQbVqfBdqWI6RLVzu7H-ARJ7FcQ==)
63. [coimbraprotocols.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGAWY0xE1sd7254O0-PVYBvAlkUCWocSqUi50Ukr6GX-KgXFl78yYkbJWmINcAv-Z08Acj7eyasv0bZ1-yaSwP9_qsS2XHCM5jyY4o0EYHM-CKhWYZ4DRPBgkwR4Z9YhHwq8VQS)
64. [overcomingms.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGvNksaYOxEU9r1IUoCftgfzwV80gs6n_OpX4RTno13qdlRFireMU8n2pEtfPsR3TcJT7nZ8UMr-9EknJNBcplFZy0F3KHe4vJS0q60b67v5hyq6RUq1ps8ZjvaFoRf_zuERmOXrxtm8Fgu2TgOv0kTGXnmCQHgXefq)
65. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFLiQtkc4nswWjagM3fqua4RcoTrUGs256Mq1RkVddjArXwJWbOOcixTuHc7PraGaQ42QyWSq_SZuGOpTRzWTZGk10HwNOcFqofzuD1qiuOBfjpP2PaO4N2yGSetFIpWtJhzzeYYjc=)
66. [grassrootshealth.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHQR98YxvNCRPLFDxxxdMzBgZJSUB7JOElI8lXHgDxTd8mQrcjGLXM_hOXG5V-_e4ZoDJr_jAA07S9SYDRcJu8eb82_Wjp8DeC0TqVFw7xPhEbgdtIqFkmbBwIJjf_3jo2z4PRPFD5s5yCfYo_-3uy68x1EcgivrOfDk8kuAO6LZGltMw==)
67. [vitamindwiki.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHwnoJRPl0e7inZrzwib6S4STwQjPGvw9ri_9Ol2VQVcyMOoZDh1Bod_2dxGO2hKS7U9-7Cl0LhoVwjYBxqijzF09o1If63We1JYfqIG-A22sWSuIhqwAZC7qy0sfTaAFr0D5MyUCUotwFyjFugJOk4dyvjfovq8ZRRnJ6L5G_4tpE5GimOWTk=)
68. [grassrootshealth.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFEyxO__VXwJx2M-t8qwmtaDc1ubiYpdQSTCzrlkW930NdchncPFLEiLP3Uio8xINJWqgmib_O5_m5FPyAceMwJg85GCcQH-4X5jwJkOx0u2MuE0gFfOdUr4dUOEcJKT5ucSuqrhw6TOu7J6kVB15zeGchCu-AUndAffDnbz8SyuDZMrhQ=)
69. [endocrine.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE6IIVZG0h93-eYlZ0Vlr7Oo1ChVobR2zXMd9nE6qfrwxe45G8eBm8Mp-3xTCOHNVh9vv54vpwmNH38mIuDW4sK-yhQ2IbX4djRmbHk7dKZM-rrRARtRYf1QpAqiEFnHJ6CTDN_zmYW2LS0h-GmJhmpQZw6Vf1vuWCTBv7iBX6_r4jXkSphSuOKgxTsW6BYkXQaV10HrlQNNLtc8ECxwWN-nvnU1EJ6dqCjGD39bhLU31h8co91AqzHYAIdWQXFieOWJgT2RFt93Fs2OOBtsg==)
70. [harvard.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEyKB-BM_rH9IAzKjCSUIGzG0PojwXFytdT3WrzscUaTAg3wNbTcRJgTcTKxCyIsI6eUGZOzEv_UyI41FFtC6_m3fzSFPuyK6-SOJ_-y-VWMKAyUcX5vOVr7sGE2ABWvek--xdt3bZuMQ8mFClksFyuzaOqWfxozQ==)
71. [tandfonline.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHS-uJenwjxUTmFIqXcfkuXt9-8u8Osf8FLa4UNeykGxCUzaTN2FKXYXUAKPYa9TKroVMzY4LxfzVyHmIyI4qwNQHvMhkUmQR3VnDlGz_54VAfYm8kT5IqcM6N_gNSJImQ6MxHbYd_3qos7DPuXC72DziVPA_nf7Q==)
72. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKgdKbcfqPa0wGUqIsDGWvNlD9lApruaQKTa4-5SPcatol-5Cfg4yOTn08YYWD8t-5xFgRMswFSLSvRzvOo3mZS2c9g2UEFdtNOu04C3gatA94SzEFRcHZeq5nssJ-QIfumWNrPd5_)
73. [tandfonline.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEOILwQA_V4xZksEkOpiG1ESdgQSUfxeeuXveNTFTsh_eNPskSXEIe4JGoJFsdWfMD_pmVeJkrSRzGKliis72UFlRo5jqsNYQuLkYH2PHEbSbVbggjaijlbzH3hNdTVdyt1-zYKdfsah8pdpu9-b_rs2VG0jS89qA==)
74. [harvard.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEtw0iBETSQFdFq5VsMzYmulLQGGSraQu5Osh4g0CNr95L8Ys11AocpcjhKqm0-WTe_Un5WxIqJlBBwKJL__Uzz095wTsi_75CGUuR9Zu1Mg0VaOqusTD5q6eRmDMYjOpIeXGMs9bn4uvGbWzZY1D1r8g6BDxx63_9HdTjn3MO_bivR52fATuCEY-F9lTtS0v9yRph1xXPZtLQWumnae_vLtfB7SAr3OUzNtS3T8Ul3wdg=)
75. [medrxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFp1GHY_f-BW2U5QmbTDyVUTvZQiNyTbiaE_Kgf7Gx-SIrtqe1g-BpjweuxI_Bwvd7_rznsJffdJsTnVtPDKwF6R9wI8WAhGtzr64wL1P4Vy6vH7WoJ5Cu1LcxGdquzF4tX59Ws4YtpYN1BwxwrQ5WP19182XJVcYkwQnI=)